Guardare, vedere, ricordare. Aspetti teorici e metodologici nello studio di elementi informativi in una scena

Rassegna della letteratura sul tema dell'informativit\ue0 degli elementi in una scena, proposta di un modello teorico che pone il concetto di potenziale informativo come fondamento dellanostra esperienza consapevole di una scen

The good, the bad and the aged: Predicting sensory quality of anhydrous milk fat by PTR/SRI-Tof-MS analysis and data mining

Due to its versatility, anhydrous milk fat (AMF) has become more popular as a food industry ingredient, but its quality control remains a critical challenge. A direct injection mass spectrometry technique was applied to predict sensory quality of AMF. Volatilome analysis through proton transfer reaction mass spectrometry (PTR-MS) was used to classify 39 industrial samples of AMF according to industrial sensory evaluation and to accelerated ageing. A selective reagent ion system was used to evaluate the suitability of PTR-MS alternative ionisation modes for quality control. Supervised multivariate data analysis successfully classified samples and showed that samples exposed to accelerated shelf life at 50 °C presented higher intensities of most volatiles, especially for the ones derived from oxidation like aldehydes and ketones, while samples with an acceptable quality level had lower emissions of volatiles. PTR-MS technique is ideal to support agroindustry sensory quality programs requiring rapid on-line analytical information.</p

The good, the bad and the aged: Predicting sensory quality of anhydrous milk fat by PTR/SRI-Tof-MS analysis and data mining

Due to its versatility, anhydrous milk fat (AMF) has become more popular as a food industry ingredient, but its quality control remains a critical challenge. A direct injection mass spectrometry technique was applied to predict sensory quality of AMF. Volatilome analysis through proton transfer reaction mass spectrometry (PTR-MS) was used to classify 39 industrial samples of AMF according to industrial sensory evaluation and to accelerated ageing. A selective reagent ion system was used to evaluate the suitability of PTR-MS alternative ionisation modes for quality control. Supervised multivariate data analysis successfully classified samples and showed that samples exposed to accelerated shelf life at 50 °C presented higher intensities of most volatiles, especially for the ones derived from oxidation like aldehydes and ketones, while samples with an acceptable quality level had lower emissions of volatiles. PTR-MS technique is ideal to support agroindustry sensory quality programs requiring rapid on-line analytical information

Combining direct-injection mass spectrometric and chromatographic techniques to investigate hazelnut volatilome evolution during roasting

The roasting is a key step in hazelnut industrial processing. It leads to major modifications in the volatile fraction composition and, therefore, the aromatic profile. An analytical strategy based on the combination of chromatographic and direct injection mass spectrometric techniques enables the characterization of hazelnut volatilome evolution during roastin

Patients with Non-Small-Cell Lung Cancer Harbouring a BRAF Mutation: A Multicentre Study Exploring Clinical Characteristics, Management, and Outcomes in a Real-Life Setting: EXPLORE GFPC 02-14

Background: Mutations in BRAF are rare oncogene mutations, found in 2% of non-small-cell lung cancers (NSCLCS). Little information is available about the management of patients with BRAF-mutated nsclc, except for those included in clinical trials. We undertook the present study to assess the clinical characteristics, management, and outcomes of those patients in a real-life setting. Methods: This retrospective multicentre observational study included all patients with BRAF-mutated nsclc diagnosed between January 2012 and December 2014. Results: Patients (n = 59) from 24 centres were included: 57.6% men; mean age: 64.5 ± 14.5 years; 82% with a performance status of 0–1 at diagnosis; smoking status: 40.3% current, 32.6% former; 93% with adenocarcinoma histology; 75% stage iv; 78% with V600E mutations; 2 with EGFR and 2 with ALK co-mutations. Of the stage iv patients, 79% received first-line therapy (14.2% anti-BRAF), and 48% received second-line treatment (23.8% anti-BRAF). Response rate and progression-free survival were, respectively, 51.7% and 8.7 months [95% confidence interval (CI): 6.4 months to 15.2 months] for first-line therapy and 35.3% and 4.1 months (95% CI: 2 months to 10.9 months) for second-line treatments. The 2-year overall survival was 58.5% (95% CI: 45.8% to 74.8%). Outcomes in patients with stage iv nsclc harbouring BRAF V600E mutations (n = 32) did not differ significantly from those of patients with other BRAF mutations. Conclusions: In this real-world analysis, most nsclc patients with a BRAF mutation were men and current or former smokers. Survival appears to be better in these BRAF-mutated patients than in nsclc patients without an oncogenic driver

Patients with Non-Small-Cell Lung Cancer Harbouring a BRAF Mutation: A Multicentre Study Exploring Clinical Characteristics, Management, and Outcomes in a Real-Life Setting: EXPLORE GFPC 02-14

International audienceBackground: Mutations in BRAF are rare oncogene mutations, found in 2% of non-small-cell lung cancers (NSCLCS). Little information is available about the management of patients with BRAF-mutated nsclc, except for those included in clinical trials. We undertook the present study to assess the clinical characteristics, management, and outcomes of those patients in a real-life setting. Methods: This retrospective multicentre observational study included all patients with BRAF-mutated nsclc diagnosed between January 2012 and December 2014. Results: Patients (n = 59) from 24 centres were included: 57.6% men; mean age: 64.5 ± 14.5 years; 82% with a performance status of 0–1 at diagnosis; smoking status: 40.3% current, 32.6% former; 93% with adenocarcinoma histology; 75% stage iv; 78% with V600E mutations; 2 with EGFR and 2 with ALK co-mutations. Of the stage iv patients, 79% received first-line therapy (14.2% anti-BRAF), and 48% received second-line treatment (23.8% anti-BRAF). Response rate and progression-free survival were, respectively, 51.7% and 8.7 months [95% confidence interval (CI): 6.4 months to 15.2 months] for first-line therapy and 35.3% and 4.1 months (95% CI: 2 months to 10.9 months) for second-line treatments. The 2-year overall survival was 58.5% (95% CI: 45.8% to 74.8%). Outcomes in patients with stage iv nsclc harbouring BRAF V600E mutations (n = 32) did not differ significantly from those of patients with other BRAF mutations. Conclusions: In this real-world analysis, most nsclc patients with a BRAF mutation were men and current or former smokers. Survival appears to be better in these BRAF-mutated patients than in nsclc patients without an oncogenic driver